Altered Gut Microbiome in Patients With Dermatomyositis

Sangmee Sharon Bae; Tien S Dong; Jennifer Wang; Venu Lagishetty; William Katzka; Jonathan P Jacobs; Christina Charles-Schoeman

doi:10.1002/acr2.11436

Altered Gut Microbiome in Patients With Dermatomyositis

ACR Open Rheumatol. 2022 Aug;4(8):658-670. doi: 10.1002/acr2.11436. Epub 2022 May 26.

Authors

Sangmee Sharon Bae¹, Tien S Dong², Jennifer Wang¹, Venu Lagishetty³, William Katzka³, Jonathan P Jacobs², Christina Charles-Schoeman¹

Affiliations

¹ University of California, Los Angeles School of Medicine, Los Angeles.
² David Geffen School of Medicine at University of California, Los Angeles and VA Greater Los Angeles Healthcare System, Los Angeles.
³ David Geffen School of Medicine at University of California, Los Angeles, Los Angeles.

Abstract

Objective: The study objective was to compare the microbial composition of patients with dermatomyositis (DM) and healthy controls (HCs) and determine whether microbial alterations are associated with clinical manifestations of DM.

Methods: The 16S ribosomal RNA gene sequencing was performed on fecal samples from patients with DM and HCs. Microbial composition and diversity were compared between subjects with DM and HCs and in association with several DM-specific clinical variables, including myositis-specific autoantibodies (MSAs). Differentially abundant microbial taxa and genes associated with clinical characteristics were identified, and functional analysis was performed using predicted metagenomics. Dietary intake was assessed using a 24-hour dietary recall.

Results: The fecal microbiome of 36 patients with DM and 26 HCs were analyzed. Patients with DM trended toward lower microbial diversity compared with HCs. The higher physician global damage score was significantly correlated with the lower microbial diversity in patients with DM. Patients with interstitial lung disease (ILD)-associated MSA (antisynthetase antibody (ab), anti-melanoma differentiation-associated protein 5 ab, n = 12) had significant differences in microbial composition and lower microbial diversity compared with HCs. Differential abundance testing demonstrated a unique taxonomic signature in the ILD-MSA subgroup, and predictive metagenomics identified functional alterations in a number of metabolic pathways. A significant increase in the relative abundance of Proteobacteria was positively correlated with multiple pathways involved in lipopolysaccharide synthesis and transport in the ILD-MSA group.

Conclusion: Patients with DM, particularly with ILD-associated MSAs, have lower microbial diversity and a distinct taxonomic composition compared with HCs. Further studies are needed to validate our findings and elucidate specific pathogenetic mechanisms that link the gut microbiome to clinical and pathological features of DM.

Abstract

Grants and funding